http://www.zibb.com/healthcare/theme/cq/Genentech+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 00:00:00 GMTMon, 23 Nov 2009 00:00:00 GMT608831http://www.zibb.com/healthcare/theme/cq/Genentech+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=185479087The biggest mergers and acquisitions witnessed so far in 2009 have been the Pfizer-Wyeth acquisition for $68 billion, Roche-Genentech $46.8 billion, Merck-Schering Plough $41B and Gilead Sciences-CV Therapeutics $1.4B. This accounted for a total of $157 billion dollars.http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=185479087Genentech IncorporatedMon, 23 Nov 2009 00:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=163403&full=1SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB - News) announced today that the U.S.http://www.biospace.com/news_story.aspx?StoryID=163403&full=1Genentech IncorporatedThu, 19 Nov 2009 12:00:00 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11061South San Francisco, Calif. and Cambridge, Mass. 18 November 2009 Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDAhttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11061Genentech IncorporatedThu, 19 Nov 2009 01:00:00 GMThttp://seekingalpha.com/article/171337-surmodics-inc-q4-2009-earnings-call-transcript?source=feedSurModics, Inc. (SRDX)Q4 2009 Earnings CallNovember 4, 2009 5:00 PM<ahttp://seekingalpha.com/article/171337-surmodics-inc-q4-2009-earnings-call-transcript?source=feedGenentech IncorporatedThu, 05 Nov 2009 01:29:07 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3496290&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3496290&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2279620359%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3496290&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3496290&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2279620359%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenentech IncorporatedThu, 22 Oct 2009 08:44:48 GMThttp://www.prnewswire.com/news-releases/peregrine-pharmaceuticals-appoints-former-genentech-senior-executive-dr-robert-garnick-as-head-of-regulatory-affairs-64728637.htmlPeregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs. - During a 24-Year Career at Genentech, Dr. Garnick was Responsible for the Approval of 17 Products Including Rituxan(R), Herceptin(R), Avastin(R) and Lucentis(R) - - Dr. Garnick tohttp://www.prnewswire.com/news-releases/peregrine-pharmaceuticals-appoints-former-genentech-senior-executive-dr-robert-garnick-as-head-of-regulatory-affairs-64728637.htmlGenentech IncorporatedMon, 19 Oct 2009 13:30:00 GMThttp://www.zibb.com/article/5599462/Peregrine+Pharmaceuticals+Appoints+Former+Genentech+Senior+Executive+Dr+Robert+Garnick+as+Head+of+Regulatory+AffairsPeregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year career at Genentech, he washttp://www.zibb.com/article/5599462/Peregrine+Pharmaceuticals+Appoints+Former+Genentech+Senior+Executive+Dr+Robert+Garnick+as+Head+of+Regulatory+AffairsGenentech IncorporatedMon, 19 Oct 2009 09:30:00 GMThttp://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/12/daily24.html?ana=from_rssRoche CEO Severin Schwan told the newspaper that compensation at Genentech, acquired by the Swiss company in March, is one of his top priorities in 2010.http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/12/daily24.html?ana=from_rssGenentech IncorporatedTue, 13 Oct 2009 18:37:39 GMThttp://www.pharmamanufacturing.com/industrynews/2009/174.html?CMP=ILC-rssBut can the head man in Basel keep R&D workers from following Genentech execs out the door?http://www.pharmamanufacturing.com/industrynews/2009/174.html?CMP=ILC-rssGenentech IncorporatedThu, 08 Oct 2009 07:00:58 GMThttp://www.pharmaceutical-business-review.com/news/amgen_presents_phase_3_trial_results_for_denosumab_090921Denosumab met all primary and secondary endpoints and demonstrated superior efficacyhttp://www.pharmaceutical-business-review.com/news/amgen_presents_phase_3_trial_results_for_denosumab_090921Genentech IncorporatedMon, 21 Sep 2009 17:19:47 GMThttp://www.genengnews.com/news/bnitem.aspx?name=63014409Biogen Idec and partners Genentech and Roche are discussing the filing of a new indication for Rituxan (rituximab) on the back of Phase III data suggesting that patients with follihttp://www.genengnews.com/news/bnitem.aspx?name=63014409Genentech IncorporatedThu, 17 Sep 2009 00:00:00 GMThttp://www.bizjournals.com/sanfrancisco/stories/2009/09/14/daily8.html?ana=from_rssBerkeley-based Xoma (NASDAQ: XOMA) said it will use $25 million from Genentech — a buyout of future royalties due from the Genentech eye drug Lucentis — plus $12.3 million from an equity financing deal, $6.1 million in restricted cash and $800,000 in unrestricted cash to repay the loan.http://www.bizjournals.com/sanfrancisco/stories/2009/09/14/daily8.html?ana=from_rssGenentech IncorporatedMon, 14 Sep 2009 18:02:11 GMThttp://biopharminternational.findpharma.com/biopharm/Online+Only/Top-10-Biologics-Sales-Top-41-billion/ArticleStandard/Article/detail/625068?ref=25Sales of the Top 10 biotech drugs exceeded $41.5 billion in 2008, according to a new report issued by BioWorld Today.http://biopharminternational.findpharma.com/biopharm/Online+Only/Top-10-Biologics-Sales-Top-41-billion/ArticleStandard/Article/detail/625068?ref=25Genentech IncorporatedWed, 09 Sep 2009 04:00:00 GMThttp://www.ft.com/cms/s/1aed8d70-7752-11de-8c68-00144feabdc0,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F1aed8d70-7752-11de-8c68-00144feabdc0.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1BASEL, Switzerland, July 23 - Roche, the maker of the Tamiflu flu drug, missed forecasts with a 29 per cent drop in first-half net profit, hit by costs related to its $47bn acquisition of Genentech.http://www.ft.com/cms/s/1aed8d70-7752-11de-8c68-00144feabdc0,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F1aed8d70-7752-11de-8c68-00144feabdc0.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1Genentech IncorporatedThu, 23 Jul 2009 07:44:50 GMThttp://www.contractpharma.com/news/2009/05/20/genentech%2c_biogen_submit_sblas_for_rituxan_in_cllTwo studies provide data for Rituxan's benefits in Progression Free Survival in chronic lymphocytic leukemia.http://www.contractpharma.com/news/2009/05/20/genentech%2c_biogen_submit_sblas_for_rituxan_in_cllGenentech IncorporatedWed, 20 May 2009 11:14:00 GMThttp://www.nieuwsbank.nl/en/2009/04/16/v012.htmRoche Media Release Basel, 16 April 2009 Roche strongly outperforms market in first quarter Genentech transaction completed, integration proceeding rapidly Roche Group · Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars) · Roche completeshttp://www.nieuwsbank.nl/en/2009/04/16/v012.htmGenentech IncorporatedWed, 15 Apr 2009 22:00:00 GMThttp://finance.yahoo.com/news/Genentech-pulls-drug-from-apf-14886742.htmlSOUTH SAN FRANCISCO, Calif. (AP) -- The Genentech unit of drugmaker Roche Holding AG is pulling the psoriasis treatment Raptiva off the U.S. market becausehttp://finance.yahoo.com/news/Genentech-pulls-drug-from-apf-14886742.htmlGenentech IncorporatedWed, 08 Apr 2009 22:53:57 GMThttp://www.topix.net/business/healthcare/2009/03/roche-holding-ag-secures-96-of-genentech-incRoche announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech .http://www.topix.net/business/healthcare/2009/03/roche-holding-ag-secures-96-of-genentech-incGenentech IncorporatedFri, 27 Mar 2009 00:23:13 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/03-26-2009/0004995414&EDATE=/PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/03-26-2009/0004995414&EDATE=Genentech IncorporatedThu, 26 Mar 2009 17:03:00 GMThttp://sanjose.bizjournals.com/sanjose/stories/2009/03/23/daily40.html?ana=from_rssRickMetrics Group Inc. of New York made the call on Basel, Switzerland-based Roche’s $46.8 billion bid to buy the 46 percent of South San Francisco-based Genentech (NYSE:DNA) that it doesn’t already own.http://sanjose.bizjournals.com/sanjose/stories/2009/03/23/daily40.html?ana=from_rssGenentech IncorporatedTue, 24 Mar 2009 21:19:57 GMThttp://www.marketwatch.com/news/story/allergan-shares-soar-glaxo-takeover/story.aspx?guid=%7B2FA1DD0C-CA7B-409A-8AF2-2334A162D253%7D&dist=msr_1Shares of Botox-maker Allergan Inc. soared in afternoon action Tuesday as rumors circulated on Wall Street that U.K. pharmaceutical giant GlaxoSmithKline PLC could be considering a bid for the company.http://www.marketwatch.com/news/story/allergan-shares-soar-glaxo-takeover/story.aspx?guid=%7B2FA1DD0C-CA7B-409A-8AF2-2334A162D253%7D&dist=msr_1Genentech IncorporatedTue, 24 Mar 2009 20:13:07 GMThttp://www.washingtonpost.com/wp-dyn/content/article/2009/03/22/AR2009032201724.html?wprss=rss_healthRockville-based Human Genome Sciences is still reeling from Wall Street's unexpected drubbing earlier this month in reaction to the biotech company's long-awaited study of a hepatitis C drug it is developing for a mass market.http://www.washingtonpost.com/wp-dyn/content/article/2009/03/22/AR2009032201724.html?wprss=rss_healthGenentech IncorporatedMon, 23 Mar 2009 04:00:00 GMThttp://www.thestreet.com/_yahoo/story/10472522/1/credit-markets-arent-stopping-health-care-ma.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NATight credit markets haven't stopped health care deals, and last week offered up another interesting chapter that involved three long picks from the Biotech Select portfolio.. Check out TheStreet for the latest stock market news and financial investment headlines.http://www.thestreet.com/_yahoo/story/10472522/1/credit-markets-arent-stopping-health-care-ma.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAGenentech IncorporatedMon, 16 Mar 2009 13:21:45 GMThttp://www.cnbc.com/id/29676840/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooShares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.http://www.cnbc.com/id/29676840/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooGenentech IncorporatedFri, 13 Mar 2009 14:48:57 GMThttp://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2009/03/13/MN4216EIEL.DTL&feed=rss.businessFor the Bay Area, the impact of Genentech's sale goes far beyond a change of nameplates on a big local company. Genentech was the region's home-grown luminary, with a leading role in the development of the nascent biotech industry of the 1970s that compares...http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2009/03/13/MN4216EIEL.DTL&feed=rss.businessGenentech IncorporatedFri, 13 Mar 2009 07:00:00 GMT